Laboratory of Virology and Infectious Disease, Center for the Study of Hepatitis C, The Rockefeller University, New York, NY 10065, USA.
Proc Natl Acad Sci U S A. 2012 Sep 4;109(36):14610-5. doi: 10.1073/pnas.1212379109. Epub 2012 Aug 20.
Dengue virus (DENV) is a global disease threat for which there are no approved antivirals or vaccines. Establishing state-of-the-art screening systems that rely on fluorescent or luminescent reporters may accelerate the development of anti-DENV therapeutics. However, relatively few reporter DENV platforms exist. Here, we show that DENV can be genetically engineered to express a green fluorescent protein or firefly luciferase. Reporter viruses are infectious in vitro and in vivo and are sensitive to antiviral compounds, neutralizing antibodies, and interferons. Bioluminescence imaging was used to follow the dynamics of DENV infection in mice and revealed that the virus localized predominantly to lymphoid and gut-associated tissues. The high-throughput potential of reporter DENV was demonstrated by screening a library of more than 350 IFN-stimulated genes for antiviral activity. Several antiviral effectors were identified, and they targeted DENV at two distinct life cycle steps. These viruses provide a powerful platform for applications ranging from validation of vaccine candidates to antiviral discovery.
登革热病毒(DENV)是一种全球性的疾病威胁,目前尚无批准的抗病毒药物或疫苗。建立依赖荧光或发光报告器的最先进的筛选系统可能会加速抗 DENV 治疗药物的开发。然而,相对较少的报告 DENV 平台存在。在这里,我们展示了可以对 DENV 进行基因工程改造以表达绿色荧光蛋白或萤火虫荧光素酶。报告病毒在体外和体内具有感染性,并且对抗病毒化合物、中和抗体和干扰素敏感。生物发光成像用于跟踪小鼠中 DENV 感染的动态,并表明该病毒主要定位于淋巴样和肠道相关组织。通过对超过 350 个 IFN 刺激基因文库进行筛选以寻找抗病毒活性,证明了报告 DENV 的高通量潜力。鉴定了几种抗病毒效应物,它们针对 DENV 的两个不同生命周期步骤。这些病毒为从验证疫苗候选物到抗病毒药物发现的各种应用提供了强大的平台。